Agilent Completes Acquisition of Biocare Medical

Agilent Technologies Inc. has successfully completed its previously announced acquisition of Biocare Medical, a global clinical pathology provider, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.

Agilent acquired Biocare in an all-cash transaction valued at $950 million to enhance its pathology portfolio. Biocare’s pathology products focus on immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) diagnostic techniques for patients with cancer. The company has developed more than 300 specialized antibodies.

“We are pleased to complete our acquisition of Biocare, which represents a natural and strategic expansion of Agilent’s pathology portfolio and strengthens our ability to serve customers across clinical and research settings,” said Agilent President and CEO Padraig McDonnell. “At Agilent, we remain focused on investing in areas where we see clear opportunities to enhance our capabilities, accelerate customer-centric innovation and create long-term value for our shareholders. With Biocare’s talented team and complementary portfolio now part of Agilent, we are well positioned to build on our momentum and further support the evolving needs of our customers and partners.”